Acorda Therapeutics Entered into a Distribution and Supply Agreement with Chance Pharmaceuticals to Commercialize Inbrija in China
Shots:
- Acorda will receive $2.5M up front, ~$6M in near-term milestones, $3M upon regulatory approval, ~$132.5M in sales milestones, and a fixed fee for each carton of Inbrija supplied to Chance. Chance Pharmaceuticals will provide Inbrija in Greater China (Mainland, Taiwan, Hong Kong, and Macao)
- Inbrija is indicated in the US for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor. Chance intends to obtain regulatory clearance shortly
- Inbrija makes use of Acorda's innovative ARCUS pulmonary delivery system for inhalation drug delivery. Additionally, Acorda also markets the branded Ampyra (dalfampridine) extended-release tablets, 10 mg
Ref: Businesswire | Image: Acorda
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
